
© 2025 Edison Investment Research
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
13:34 | Mendus (OMX: IMMU) presents DCOne platform update | On 3 April 2025, Mendus has announced that the company presented data from its proprietary DCOne platform at the Immunotherapy of Cancer Conference. The presentation showcased the potential of the platform... ► Artikel lesen | |
21.02. | Mendus - CADENCE trial enrols first patient | Mendus has announced that the first patient has been enrolled in the CADENCE trial, sponsored by the Australasian Leukaemia and Lymphoma Group (ALLG). This is a multi-centre, randomised, controlled... ► Artikel lesen | |
21.02. | Mendus (OMX: IMMU) notes first patient enrolment in the CADENCE trial | Mendus has announced that the first patient has been enrolled in the Phase II AMLM22-CADENCE trial, sponsored by the Australasian Leukaemia and Lymphoma Group. The trial is a multicentre, randomised... ► Artikel lesen | |
20.02. | Mendus - Vididencel on track in AML going into 2025 | Mendus has reported its FY24 results, reflecting an active period. Lead programme, vididencel in acute myeloid leukaemia (AML), had encouraging data from the ADVANCE II trial in December, laying the... ► Artikel lesen | |
13.02. | Mendus - Focus firmly on pivotal-stage readiness in 2025 | Mendus's FY24 results and subsequent management presentation highlighted its focus on advancing lead asset, vididencel, to pivotal-stage readiness. Backed by robust long-term monotherapy data from ADVANCE... ► Artikel lesen |